An interventional study of propranolol and Placebo in Healthy Subjects, sponsored by Kristian Kjær Petersen. Completed at 1 site in Denmark. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-28.
Sponsored by Kristian Kjær Petersen · Not applicable, Interventional, and Basic science
An extensive amount of studies indicate that conditioned pain modulation (CPM) test paradigms can be of use to evaluate the efficacy of the endogenous pain inhibition pathway in healthy controls and pain patients. A number of studies indicate that the autonomic nervous system (ANS) responds to painful stimulation by parasympathetic activity withdrawal and up-regulation of sympathetic activity (flight-or-fight mode), but it remains unknown whether these responses predict individual pain susceptibility or CPM efficacy and whether different pain modalities evoke different physiological stress responses, i.e. do individuals with low pain tolerance exhibit more vigorous ANS responses when subjected to controlled acute pain stimuli, and do high ANS responsiveness to pain coincide with altered psychophysical pain levels/CPM efficacy.
This study aims to investigate the effect of ANS responsiveness on CPM paradigms and to investigate if an exogenous, pharmaceutically induced decrease in the sympathetic drive of the ANS will yield decreased CPM efficacy.
Kristian Kjær Petersen is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Propranolol is a beta-blocker
Drug: propranolol
Placebo
Drug: Placebo
Reduction of the ANS response
CPM efficacy
A test stimuli will be applied and compared with a test stimuli simultaneous a condition stimuli.
Time frame: 1-2 hours after propranolol/placebo and after 10 minutes break.
Temporal summation of pain
10 stimuli will be applied and subjects will back asked to rate the pain for each individual stimuli.
Time frame: 1-2 hours after propranolol/placebo and after 10 minutes break.
Heart-rate variability
Two-point Heart-rate variability recording will be conducted using the Polar RS800CX heart rate monitor.
Time frame: 1-2 hours after propranolol/placebo and after 10 minutes break.
Offset analgesia
Temperatures ranging from 45-48°C will be applied to the forearm in three phases (phase 1: 5 seconds, phase 2: 5 seconds, and phase 3: 20 seconds). The subjects will be asked to assess the pain of the thermal stimuli using the electronic VAS scale.
Time frame: 1-2 hours after propranolol/placebo and after 10 minutes break.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kristian Kjær Petersen